top digital currency 2016 Top stories

Shangpin home delivery and Shulan signed a strategic cooperation agreement. According to Shangpin home delivery, on December 11th, Shangpin home delivery and Shulan formally signed a strategic cooperation agreement at Changshun Group headquarters. The two sides will break through the customized track, explore the path of "customization+software" integration and co-construction, jointly explore market channels, and provide consumers with more convenient, personalized and professional home solutions through integrated and integrated ecological scenarios.The game and media sectors moved up three boards in vision china, three boards in vision china, Fuchun, Reader Media, Zhewen Internet and Guangdong Media, and Kaiying Network, Shengguang Group and Tianlong Group followed suit.The Philippine side's provocation and China's counter-measures will be one step stronger. The Philippine Coast Guard said that China has recently launched "aggressive actions" against Philippine fishing boats heading for the reef. Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, said today that the Philippine side likes to take a boat full of journalists wherever it goes, whether it is sailing or shipping, but the key is not to see who has more journalists, but to see who is more reasonable and legal. China Nansha Islands and Huangyan Island have never been included in the territory of the Philippines, which is determined by a series of international treaties. The Philippines is well aware of this. China's attitude is clear and definite: one point for provocation and one step for counter-attack; If you are stubborn, you will be with me to the end.

Rambler: We have always taken a proactive attitude towards all kinds of co-branded products. rambler said at the shareholders' reception day on December 12 that the company has always taken a proactive attitude towards all kinds of co-branded products, and the future co-branded products will be deeper and closer.Good wife set up an intelligent technology company in Quanzhou, and the enterprise search APP shows that Quanzhou Sunguest Intelligent Technology Co., Ltd. was established recently, with the legal representative of Cao Caifeng and the registered capital of 500,000 yuan. Its business scope includes: engineering and technical research and experimental development; Network and information security software development; Software development; Digital technology services, etc. Enterprise equity penetration shows that the company is wholly owned by Haotai.Affected by martial law, the support rate of South Korean President Yin Xiyue fell to a record 11%.

Visionox: Chengdu Chenxian Micro-LED production line has entered the sprint stage of mass production and shipment. Visionox (002387) said on the interactive platform on December 13th that the first TFT-based Micro-LED production line in Chengdu Chenxian, a shareholding company, completed the equipment moving in in September this year and is now entering the sprint stage of mass production and shipment.The 30-year Treasury ETF rose sharply at the opening, hitting a record high. Both "Boshi SSE 30-year Treasury ETF" and "Pengyang China Bond -30-year Treasury ETF" rose by 0.65%.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)